Effect of vericiguat on cardiovascular outcomes in patients with heart failure with and without diabetes: Insights from the VICTORIA trial

被引：0

作者：

Khan, S. ^{[1
]}

Butler, J. ^{[2
]}

Young, R. ^{[1
]}

Lewis, B. S. ^{[3
]}

Escobedo, J. ^{[4
]}

Refsgaard, J. ^{[5
]}

Reyes, E. ^{[6
]}

Roessig, L. ^{[7
]}

Blaustein, R. O. ^{[8
]}

Lam, C. S. P. ^{[9
]}

Voors, A. A. ^{[10
]}

Ponikowski, P. ^{[11
]}

Anstrom, K. J. ^{[1
]}

Armstrong, P. ^{[12
]}

机构：

[1] Duke Clin Res Inst, Durham, NC USA

[2] Baylor Univ, Med Ctr, Dallas, TX USA

[3] Lady Davis Carmel Med Ctr, Haifa, Israel

[4] Univ Nacl Autonoma Mexico, Mexico City, DF, Mexico

[5] Reg Hosp Viborg, Viborg, Denmark

[6] Philippine Gen Hosp, Manila, Philippines

[7] Bayer AG, Wuppertal, Germany

[8] Merck & Co Inc, Rahway, NJ USA

[9] Duke Natl Univ Singapore, Natl Heart Ctr Singapore, Singapore, Singapore

[10] Univ Med Ctr Groningen, Groningen, Netherlands

[11] Wroclaw Med Univ, Wroclaw, Poland

[12] Univ Alberta, Edmonton, AB, Canada

来源：

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：2